ProfusaPFSA -16.54%8 EBIT per Share is $-1,577.24 as of Mar. 2026. GuruFocus rates PFSA with a GF Score™ of 8/100. The stock has 3 warning signs investors should review. Among 687 Medical Devices & Instruments companies, Profusa ranks worse than 96.94% on this metric.
Profusa's EBIT per Share for the
three
months ended in Mar. 2026 was $-50.56.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-1,577.24.
During the past 3 years, the average EBIT per Share Growth Rate was -56.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Profusa's EBIT per Share or its related term are showing as below:
PFSA'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -56.6 Med: -14.65 Max: 27.3
Current: -56.6
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Profusa was 27.30% per year. The lowest was -56.60% per year. And the median was -14.65% per year.
PFSA's 3-Year EBIT Growth Rate is ranked worse than 96.94% of 687
companies
in the Medical Devices & Instruments industry
Industry Median: 9.4
vs PFSA: -56.60
Profusa's EBIT for the
three
months ended in Mar. 2026 was $-3.44 Mil.
Profusa (NAS:PFSA) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Profusa EBIT per Share Related Terms
Profusa EBIT per Share Historical Data
* Premium members only.
The historical data trend for Profusa's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,577.24
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Profusa (PFSA) has a EBIT per Share of $-1,577.24 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Profusa and its competitors. According to the industry distribution chart, Profusa ranks #666 out of 687 companies in the Medical Devices & Instruments industry, placing it in the top 96.9%.
Is Profusa's EBIT per Share too high?
Profusa's current EBIT per Share is $-1,577.24. Based on the distribution chart, Profusa ranks #666 out of 687 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Profusa has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Profusa's EBIT per Share compare to ODYY and SSKN?
According to the Medical Devices & Instruments industry distribution chart, Profusa ranks #666 out of 687 companies for EBIT per Share. This places Profusa in the lower half of its industry. The industry median EBIT per Share is 9.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.40, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Profusa and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profusa's current EBIT per Share is $-1,577.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profusa stock overvalued right now?
Profusa (PFSA) has a current EBIT per Share of $-1,577.24. The current EBIT per Share is $-1,577.24. Profusa's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Profusa (PFSA), the current EBIT per Share is $-1,577.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.
8GF Score
Get the complete analysis for PFSA
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PFSA has been successfully added to your 
